Compare GeneDx Holdings Corp (WGS) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs State Street PDR S&P Retail ETF — how do they compare? GeneDx Holdings Corp trades at $67.97 (market cap $2.02B), while State Street PDR S&P Retail ETF trades at $83.73 (market cap $389.66M). The key difference: GeneDx Holdings Corp is far larger — about 5.2× State Street PDR S&P Retail ETF's market cap, and State Street PDR S&P Retail ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| WGS | XRT | |
|---|---|---|
Market Cap | $2.02B | $389.66M |
Volume | 734,640 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $167.51 | $92.35 |
52-Week Low | $34.51 | $77.28 |
Typical Hold Time | 19 Days | 44 Days |
Enterprise Value | $2.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
XRT (SPDR S&P Retail ETF) trades at $83.45, up 0.65% with a bullish technical signal despite bearish moving averages. The ETF faces mixed sentiment as retail sales show volatility, with August's 1.2% rebound contrasting July's 0.6% decline. Key resistance sits at $85, while RSI-6 at 84.45 indicates potential overbought conditions. Recent news highlights holiday sales projections exceeding $1 trillion but concerns over consumer spending shifts toward value-oriented purchases.
Outlook remains cautious amid macroeconomic pressures; higher interest rates and inflation weigh on consumer sentiment, with analysts expecting continued underperformance versus broader markets. The ETF's equal-weight approach provides diversification, but selective consumer spending patterns and oil price volatility pose near-term risks. Investment appeal hinges on holiday season performance and Federal Reserve policy direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
